Why the study?
What is the prevalence and functional consequence of somatic CTNNB1 mutations in aldosterone-producing adenomas?
What is the prevalence and functional consequence of somatic CTNNB1 mutations in aldosterone-producing adenomas?
Somatic CTNNB1 mutations occur in approximately 5% of aldosterone-producing adenomas, driving aberrant WNT signaling and contributing to secondary hypertension.
No takes yet. Share an insight, caveat, or question.
CTNNB1 mutations may mark a WNT-driven APA subset; hypothesis-generating and requires prospective validation before clinical use.
Åkerström et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: